Clinical Trials · NCT00518882
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 467
- Start date
- Aug 2007
- Locations
- 125 sites, 16 countries
- Primary endpoint
- Change in Glycosylated A1c (HbA1c) at Week 26